AR077635A2 - Hidrato a de aripiprazol - Google Patents

Hidrato a de aripiprazol

Info

Publication number
AR077635A2
AR077635A2 ARP100102387A ARP100102387A AR077635A2 AR 077635 A2 AR077635 A2 AR 077635A2 AR P100102387 A ARP100102387 A AR P100102387A AR P100102387 A ARP100102387 A AR P100102387A AR 077635 A2 AR077635 A2 AR 077635A2
Authority
AR
Argentina
Prior art keywords
hydrate
aripiprazol
hydration
endothermic curve
spectrum
Prior art date
Application number
ARP100102387A
Other languages
English (en)
Inventor
Kenji Tomikawa
Masanori Takahashi
Kaoru Abe
Tomonori Nakagawa
Koichi Shinhama
Naoto Utsumi
Michiaki Tominaga
Yoshihiro Oi
Shohei Yamada
Satoshi Aoki
Junichi Kawasaki
Makoto Ishigami
Youichi Taniguchi
Tsuyoshi Yabuuchi
Kiyoshi Fujimoto
Yoshihiro Nishioka
Noriyuki Kobayashi
Tsutomu Fujimura
Takuji Bando
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36049773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077635(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR077635A2 publication Critical patent/AR077635A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Hidrato A de Aripiprazol y proceso de preparacion. Reivindicacion 1: Hidrato A de Aripiprazol, caracterizado porque dicho Hidrato A tiene: un espectro de difraccion de rayos X en polvos con picos característicos en 2q: 12,6s, 15,4s, 17,3s, 18,0s, 18,6s, 22,5s, 27,8s; bandas de absorcion infrarroja particulares en 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963 y 784 cm-1 en el espectro IR (KBr); una curva endotérmica que es sustancialmente la misma que la curva endotérmica del análisis térmico diferencial/termogravimétrico (velocidad de calentamiento 5sC/min.) indicada en la figura; un tamano de partícula medio de 50 mm o menos.
ARP100102387A 2001-09-25 2010-07-05 Hidrato a de aripiprazol AR077635A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001290645 2001-09-25
JP2001348276 2001-11-14
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
AR077635A2 true AR077635A2 (es) 2011-09-14

Family

ID=36049773

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP090103228A AR073111A2 (es) 2001-09-25 2009-08-21 La preparacion oral solida farmaceutica conteniendo cristales de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ARP100102387A AR077635A2 (es) 2001-09-25 2010-07-05 Hidrato a de aripiprazol
ARP120102986A AR087544A2 (es) 2001-09-25 2012-08-15 Cristales de aripiprazol anhidro b

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090103228A AR073111A2 (es) 2001-09-25 2009-08-21 La preparacion oral solida farmaceutica conteniendo cristales de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP120102986A AR087544A2 (es) 2001-09-25 2012-08-15 Cristales de aripiprazol anhidro b

Country Status (21)

Country Link
EP (1) EP3081216A1 (es)
KR (2) KR100530731B1 (es)
CN (12) CN103751118A (es)
AR (3) AR073111A2 (es)
CA (1) CA2713466C (es)
CL (1) CL2010000405A1 (es)
CY (4) CY1110212T1 (es)
DK (1) DK1925308T3 (es)
ES (1) ES2596354T3 (es)
HK (5) HK1203059A1 (es)
IL (3) IL204707A (es)
LT (1) LT1925308T (es)
MY (1) MY138669A (es)
NO (1) NO337844B1 (es)
PE (1) PE20030445A1 (es)
PH (1) PH12014500782A1 (es)
PL (7) PL393607A1 (es)
PT (1) PT1925308T (es)
RU (1) RU2279429C2 (es)
SI (1) SI1927357T1 (es)
TW (2) TWI318572B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR102128883B1 (ko) * 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3638447B2 (ja) * 1998-09-10 2005-04-13 積水ハウス株式会社 笠木取付金具および笠木取付構造
GB9930061D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Quinolone compounds for use in treating viral infections
NZ519981A (en) * 2000-01-20 2005-02-25 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
JP2002193915A (ja) * 2000-12-28 2002-07-10 Otsuka Pharmaceut Co Ltd ベンゼンスルフォナート化合物

Also Published As

Publication number Publication date
NO337844B1 (no) 2016-06-27
CN104945321A (zh) 2015-09-30
CN103751119A (zh) 2014-04-30
TWI318572B (en) 2009-12-21
EP3081216A1 (en) 2016-10-19
CY1110212T1 (el) 2015-01-14
PL393596A1 (pl) 2011-04-26
IL204707A0 (en) 2010-11-30
HK1136960A1 (en) 2010-07-16
ES2596354T3 (es) 2017-01-09
TW200942238A (en) 2009-10-16
RU2279429C2 (ru) 2006-07-10
HK1092808A1 (en) 2007-02-16
CN103288727B (zh) 2016-04-27
HK1203060A1 (en) 2015-10-16
IL204707A (en) 2016-06-30
NO20141193L (no) 2003-01-17
HK1136959A1 (en) 2010-07-16
PL230869B1 (pl) 2018-12-31
AR073111A2 (es) 2010-10-13
CL2010000405A1 (es) 2010-10-15
PL393603A1 (pl) 2011-04-26
HK1136958A1 (en) 2010-07-16
CN105267151A (zh) 2016-01-27
CN103288727A (zh) 2013-09-11
CY1110208T1 (el) 2015-01-14
PL221521B1 (pl) 2016-04-29
HK1215397A1 (zh) 2016-08-26
CN103755632A (zh) 2014-04-30
HK1223043A1 (zh) 2017-07-21
CY1110244T1 (el) 2015-01-14
SI1927357T1 (sl) 2010-09-30
HK1129891A1 (en) 2009-12-11
PT1925308T (pt) 2016-10-24
KR100490222B1 (ko) 2005-05-18
CN104306374A (zh) 2015-01-28
PL393607A1 (pl) 2011-03-14
HK1196128A1 (zh) 2014-12-05
HK1203059A1 (en) 2015-10-16
RU2004126636A (ru) 2006-02-10
CN103751118A (zh) 2014-04-30
PL219565B1 (pl) 2015-05-29
KR20040053372A (ko) 2004-06-23
PL393598A1 (pl) 2011-04-26
HK1187048A1 (zh) 2014-03-28
CN103751093A (zh) 2014-04-30
PL417178A1 (pl) 2016-07-04
KR100530731B1 (ko) 2005-11-23
CN104306337A (zh) 2015-01-28
AR087544A2 (es) 2014-04-03
HK1129889A1 (en) 2009-12-11
CN105832677A (zh) 2016-08-10
HK1136961A1 (en) 2010-07-16
CN103755632B (zh) 2016-06-29
CN102579446A (zh) 2012-07-18
IL225902A0 (en) 2013-06-27
MY138669A (en) 2009-07-31
DK1925308T3 (en) 2016-12-12
PL393601A1 (pl) 2011-04-26
CN103191118A (zh) 2013-07-10
KR20030060871A (ko) 2003-07-16
HK1210468A1 (en) 2016-04-22
PL393608A1 (pl) 2011-03-14
PL219564B1 (pl) 2015-05-29
LT1925308T (lt) 2016-11-10
CA2713466C (en) 2012-01-03
CY1110070T1 (el) 2015-01-14
CA2713466A1 (en) 2003-04-03
TWI332839B (en) 2010-11-11
IL234770A0 (en) 2014-11-30
PE20030445A1 (es) 2003-07-26
PH12014500782A1 (en) 2018-09-10
PL221536B1 (pl) 2016-04-29

Similar Documents

Publication Publication Date Title
IL164534A0 (en) Novel boehmite particles and polymer materials incorporating same
AR077635A2 (es) Hidrato a de aripiprazol
DE69905739D1 (de) Naphthopyrane die in c5-c6 anneliert sind, ihre herstellung sowie sie enthaltende zubereitungen und (co)polymermatrizen
AU2003279807A1 (en) Nanocrystals in ligand boxes exhibiting enhanced chemical, photochemical, and thermal stability, and methods of making the same
EP0806489A3 (en) Process for making improved copper/tungsten composites
TWI264568B (en) Optical compensatory sheet comprising polymer film
PT1017625E (pt) Processo hidrotermico para o fabrico de pos de titanato de bario
AU2003293757A1 (en) Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
DK1406848T3 (da) Termisk isolation indeholdende supplerende IR-absorberende materiale
AU2524201A (en) Lithography device which uses a source of radiation in the extreme ultraviolet range and multi-layered mirrors with broad spectral band in this range
AU2003254864A1 (en) Novel triarylamine polymer, process for producing the same, and use thereof
CA2314339A1 (en) N-benzyl-3-indenylacetamide derivatives for treating neoplasia
AU2002318742A1 (en) Pullulan-containing powder, process for producing the same and use thereof
AU7162387A (en) Quinolinyl ether or thioether tetrazoles as agents for the treatment of hypersensitive ailments
MXPA05006233A (es) Carbonato de calcio ultraseco y su uso como aditivo para el control reologico.
AU2002301811A1 (en) Aluminum hydroxide aggregated particles, process for producing the same, vessel used therefor, and process for producing aluminum hydroxide powder
IL162633A (en) Peptides for the treatment of cancer associated with the human papilloma virus (hpv) and other epithelial tumours
CN212755104U (zh) 一种带有感应开关的化妆镜
CN217030897U (zh) 一种复合石墨烯涂层的杀菌、去甲醛防蓝光led灯
AU639760B2 (en) Sodium perborate
BR0207630A (pt) Processo para a preparação de compostos de inclusão entre um fármaco e ciclodextrina por meio de tratamento com microondas
AU6337296A (en) Crystals of fragments of cd40 ligand and their use
MXPA05012697A (es) Medio de grabado optico.
JPS55164238A (en) Agricultural vinyl chloride resin film
AU2002337138A1 (en) Window shutter or sliding shutter

Legal Events

Date Code Title Description
FC Refusal